Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.81 |
| ▸ | RAF1 | P04049 | 1/20 | 0.73 |
| ▸ | BRAF | P15056 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 10/20 | 0.70 |
| ▸ | RET | P07949 | 6/20 | 0.70 |
| ▸ | KIF5B | P33176 | 5/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.69 |
| ▸ | JAK3 | P52333 | 2/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.69 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.69 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.69 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.69 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.69 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 3/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478005 | 0.90 | EGFR (1.00) | EGFRKDRRETKIF5BRIPK2 | |
| Hydrochloric Acid SCHEMBL29623261 | 0.88 | EGFR (1.00) | EGFRKDRRETKIF5BRIPK2 | |
| Hydrochloric Acid SCHEMBL5471121 | 0.88 | EGFR (1.00) | EGFRKDRRETKIF5BRIPK2 | |
| SCHEMBL9478 | 0.88 | EGFR (0.77) | EGFRRAF1BRAFKDRRET | |
| SCHEMBL5242610 | 0.88 | KDR (0.81) | EGFRRAF1KDRRETKIF5B | |
| SCHEMBL5239599 | 0.87 | EGFR (0.80) | EGFRRAF1BRAFKDRRET | |
| SCHEMBL15946888 | 0.86 | EGFR (0.83) | EGFRRAF1BRAFKDRRET | |
| SCHEMBL20792806 | 0.86 | EGFR (0.87) | EGFRRAF1BRAFKDRRET | |
| SCHEMBL8383 | 0.85 | EGFR (0.83) | EGFRRAF1BRAFKDRRET | |
| SCHEMBL14515606 | 0.85 | KDR (0.72) | EGFRRAF1BRAFKDRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780342-B1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-06-01 | — | — | EP | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| EP-2780342-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| WO-2013071697-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013071697-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | ABL1, PRKDC, JAK2 | EGFR 460/4885RAF1 118/4885BRAF 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.